Investment Rating - The report does not explicitly state an investment rating for the pericarditis drug industry in China Core Insights - The pericarditis drug market in China is projected to grow from 22.2 billion RMB in 2022 to 30.63 billion RMB by 2027, reflecting a compound annual growth rate (CAGR) of approximately 7.85% [15][19] - The incidence rate of pericarditis is expected to increase from 4.79% in 2020 to 5.38% by 2027, indicating a growing patient population [19][21] - The average annual drug cost for pericarditis patients is projected to decrease from 0.03 million RMB in 2022 to 0.02 million RMB by 2027, suggesting cost containment measures or changes in treatment protocols [21][23] Market Size Overview - The market size for pericarditis drugs in China from 2017 to 2027 is as follows: - 2017: 12.29 billion RMB - 2018: 13.81 billion RMB - 2019: 15.09 billion RMB - 2020: 16.48 billion RMB - 2021: 18.22 billion RMB - 2022: 20.08 billion RMB - 2023E: 21.62 billion RMB - 2024E: 26.25 billion RMB - 2025E: 28.4 billion RMB - 2026E: 30.63 billion RMB - 2027E: 30.63 billion RMB [15][19] Population and Incidence Rate - The total population in China is projected to remain relatively stable, with slight increases from 141,175 million in 2022 to 142,348 million by 2027 [17] - The incidence rate of pericarditis is expected to rise steadily, with a notable increase from 4.9% in 2023E to 5.38% in 2027E [19][21] Drug Penetration Rate - The penetration rate of pericarditis drugs is anticipated to grow from 9.11% in 2022 to 23.12% by 2027, indicating an increasing adoption of treatment options [23] Average Drug Costs - The average annual drug cost for pericarditis is projected to decrease from 0.03 million RMB in 2022 to 0.02 million RMB by 2027, reflecting potential changes in treatment strategies or drug pricing [21][23]
中国心包炎药物行业市场规模测算逻辑模型 头豹词条报告系列
Tou Bao Yan Jiu Yuan·2024-09-26 12:30